The higher rate of Ki67 intermediate category by the global method has been interpreted in the 2022 Swedish clinical decision tree recommending gene expression profiling for patients with Grade II, Ki67 intermediate, T1c / T2 breast cancer (Supplementary 3). This evidence concerns the gene MKI67 and breast cancer.